Breakthrough Triple Therapy Cures Pancreatic Cancer in Mice Without Major Side Effects

In a landmark preclinical study, researchers have achieved a complete and lasting eradication of pancreatic cancer tumours in mice using a novel triple combination therapy, offering fresh hope in the fight against one of the deadliest forms of cancer.

Published in the Proceedings of the National Academy of Sciences (PNAS), the research was led by Dr Mariano Barbacid and his team at the Spanish National Cancer Research Centre (CNIO). The scientists tackled a major obstacle in pancreatic cancer treatment, treatment resistance, by targeting the cancer's molecular mechanisms at multiple levels.

A New Strategy Against Resistance

Existing targeted drugs can initially shrink pancreatic tumours, but often stop working as the cancer adapts. In contrast, the CNIO team developed a therapy that simultaneously blocks the cancer-promoting KRAS signalling pathway at three points, significantly reducing the tumour's ability to evade treatment.

The triple therapy combines:

An experimental KRAS inhibitor (daraxonrasib),
An existing lung cancer drug (afatinib), and
A protein degrader (SD36).

When given together to three different mouse models of pancreatic ductal adenocarcinoma (PDAC), the most common and lethal type of pancreatic cancer, the treatment caused dramatic tumour regression with no significant toxic side effects.

Dr Barbacid and colleagues observed that the tumours not only shrank but disappeared, and most importantly, did not develop resistance to the treatment, a persistent issue with current therapies. The study's authors describe the results as a foundation for designing combination therapies that could improve survival in humans.

What This Means for Patients

While the findings represent a major scientific milestone, the researchers note that human clinical trials have not yet begun. Optimising triple therapy for safety and effectiveness in people will take time, and regulatory approval remains a long way off. However, these results pave the way for next-generation treatment strategies that could significantly improve patient outcomes.

Global Burden of Pancreatic Cancer: A Silent Killer

Pancreatic cancer continues to be a significant worldwide health concern:

Pancreatic cancer is the 12th most frequent cancer worldwide.
Tragically, the disease accounted for nearly 470,000 deaths in the same year, reflecting its highly aggressive nature and poor prognosis.
Due to delayed diagnosis and few available treatments, pancreatic cancer is one of the leading causes of cancer-related death worldwide.

Most patients are diagnosed at advanced stages because early symptoms are often vague or nonexistent. This has kept survival rates low, even as research progresses steadily toward earlier detection and more effective therapies.

What's Next? Hope on the Horizon

The CNIO team's work contributes to a growing body of research seeking to revolutionise pancreatic cancer care, from immunotherapies to early-detection tests. While clinical applicability remains a future goal, success in animal models represents a significant scientific advance and offers renewed hope for patients and clinicians alike.

MediGence's Commitment to Advancing Cancer Care

At MediGence, we work hard to provide our viewers, particularly those affected by complex illnesses such as pancreatic cancer, with the most recent advancements in global healthcare. This encouraging study emphasises how crucial it is to keep funding cutting-edge treatments and international cooperation in order to enhance patient outcomes everywhere.

Patients can receive cancer treatment at MediGence regardless of their location. We facilitate people's access to cutting-edge treatments, second opinions, and individualised care plans by connecting them with world-class pancreatic cancer specialists and oncology hospitals. MediGence is a reliable link to world-class medical excellence, enabling patients to make informed choices and obtain the best care possible, whether you are investigating cutting-edge treatments, clinical knowledge, or foreign treatment possibilities.